

Practitioner's Docket No. MPI00-343P1RM

REMARKS

Claims 1, 2, and 6-11 remain pending and under consideration. Claim 10 has been amended to recite the term "isolated." The specification has been amended to correct typographical errors resulting in misspelling of "ACTR." Additionally, the specification has been amended to remove reference to an embedded hyperlink.

Applicants appreciate the time taken by supervisory Examiner Kathleen Kerr and Quality Specialist Michael Woodward to review and consider the present application. In response to telephone and facsimile message from Examiner Kerr, the present amendments to claim 10 and the specification are being filed. The amendments contained herein specify the host cell of claim 10 is an isolated host cell, so as to not read on gene therapy-type claim interpretations. Furthermore, misspelled references to "ACTR-1" in the specification have been corrected. It is Applicant's understanding following Examiner Kerr's message that the present amendments render the application in condition for allowance.


This paper is being filed timely as a one month extension of time is filed concurrently herewith. It is believed no additional fees or extensions of time are required. In the event any additional fees or extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray  
Registration No. 47,066  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-551-3676  
Facsimile - 617-551-8820

31 August 2005

(Page 6 of 6)